Synopsis

Objective
To determine whether increased disease control in 
psoriasis with treatment translates into improvements in 
quality of life. 

Methods
Patients reaching different absolute PASI thresholds were 
assessed for simultaneous achievement of DLQI 0/1.

Results

Week 52

Conclusion
Patients treated with bimekizumab more frequently 
achieved PASI≤2 by Week 52, with the majority of these 
patients also achieving DLQI 0/1.

Objective
To examine how improved disease control translates to greater quality of life in 
patients with moderate to severe plaque psoriasis receiving bimekizumab compared 
with ustekinumab and placebo.

Background
• Psoriasis negatively impacts patients’ quality of life,1 and therefore it is important to 

determine whether improvements in disease control achieved with treatment may 
also be reflected in greater quality of life.  

• Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin 
(IL)-17F in addition to IL-17A, both of which have a pivotal role in psoriasis 
immunopathogenesis.2-5

• Absolute Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality 
Index (DLQI) were assessed in patients with moderate to severe plaque psoriasis 
being treated with bimekizumab versus (vs) ustekinumab and placebo.

Methods
• In BE VIVID (NCT03370133) patients were randomized to bimekizumab through 

Week 52, ustekinumab through Week 52 or placebo; patients randomized to 
placebo switched to bimekizumab at Week 16 (Figure 1). 

• Psoriasis severity was assessed by PASI, where PASI=0 indicated complete skin 
clearance and PASI≤2, a relevant disease endpoint for a treat to target approach in 
psoriasis,6 indicated disease control.

• Patients completed the DLQI questionnaire throughout treatment; DLQI of 0 or 1 
indicated no impact on quality of life.7

• To evaluate how clinical response translates into health-related quality of life in 
these post hoc analyses, patients achieving DLQI 0/1 were grouped by PASI=0, 
PASI≤2, 2<PASI<5, and PASI≥5 responses at the same timepoint. 

• Weeks 4 and 16 data for all patients, and Week 52 data for bimekizumab- and 
ustekinumab-randomized patients, are presented here.

Results
Patient Population

• In BE VIVID, 321 patients were randomized to bimekizumab, 163 to ustekinumab, 
and 83 to placebo (Table 1).

PASI and DLQI Outcomes

• At Week 4, after one dose, a greater proportion of bimekizumab-treated 
patients rapidly achieved superior rates of PASI=0 and PASI≤2 as compared 
to ustekinumab (nominal p<0.0001 for both) and placebo (nominal p=0.0019 
and nominal p<0.0001, respectively); this was further improved and sustained 
through Week 16 to Week 52 (Table 2).

• Similarly, rapid improvements in quality of life were seen with bimekizumab; 
DLQI 0/1 achievement by Week 4 was greater with bimekizumab as compared to 
ustekinumab and placebo (nominal p<0.0001 for both). Quality of life continued 
to improve through to Week 52, and remained greater in bimekizumab patients vs 
ustekinumab (nominal p=0.0007) (Table 2).

• Across all treatment arms, higher disease control translated into greater 
improvements in quality of life. This was more pronounced in bimekizumab 
than ustekinumab with 44.6% vs 17.3% achieving both PASI=0 and DLQI 
0/1 at Week 16, increasing to 68.6% vs 40.3% at Week 52 (Figure 2). Similar 
trends were seen when considering PASI≤2; 65.1% of patients treated with 
bimekizumab vs 34.6% with ustekinumab achieved both PASI≤2 and DLQI 0/1 
at Week 16, increasing to 83.8% vs 59.7% at Week 52 (Figure 3).

Conclusions
Greater levels of disease control seen with bimekizumab treatment, as compared to 
ustekinumab, translated to greater quality of life as measured by DLQI.

After one year of treatment with bimekizumab, almost 70% of patients achieved 
complete skin clearance and reported that psoriasis had no impact on their quality of 
life, compared to 40% with ustekinumab.

K. Gordon,1 P. Foley,2 P. Rich,3 K. Duffin,4 A. Pinter,5 C.E.M. Griffiths,6 
M. Wang,7 V. Vanvoorden,8 F. Staelens,9 V. Ciaravino,10 J.F. Merola11

BSA: body surface area; DLQI: Dermatology Life Quality Index; IGA: Investigator’s Global Assessment; OC: observed case; PASI: Psoriasis Area and Severity Index; Q4W: every 4 weeks; Q12W: every 12 weeks; SD: standard deviation; vs: versus.

Figure 1 Study design

Institutions: 1Medical College of Wisconsin, Milwaukee, Wisconsin, USA; 2The University of Melbourne, St. Vincent’s Hospital Melbourne, Fitzroy and Probity Medical Research Inc., Skin Health Institute, Carlton, Victoria, Australia; 3Oregon Dermatology and Research Center, Portland, Oregon, USA; 4Department of Dermatology, University of Utah, Salt Lake City, 
Utah, USA; 5University Hospital Frankfurt, Frankfurt am Main, Germany; 6Dermatology Centre, The University of Manchester, Manchester, UK; 7UCB Pharma, Raleigh, North Carolina, USA; 8UCB Pharma, Brussels, Belgium; 9UCB Pharma, Braine-l’Alleud, Belgium; 10UCB Pharma, Colombes, France; 11Harvard Medical School, Brigham and Women’s Hospital, Boston, 
Massachusetts, USA

Bimekizumab Versus Ustekinumab in Plaque Psoriasis: Lasting Efficacy 
Translates to Rapid and Sustained Improvements in Quality of Life in the  
BE VIVID Multicenter, Randomized, Double-Blinded Phase 3 Trial

Presented at Winter Clinical 2021 Virtual Congress  |  January 16–24

References: 1Bhosle MJ. Health Qual Life Outcomes 2006;4:35; 2Glatt S. Br J Clin Pharmacol 2017;83:991–1001; 3Papp KA. J Am Acad Dermatol 2018;79:277–86.e10; 4Durham L. Curr Rheumatol Rep 2015;17:55; 5Fujishima S. Arch Dermatol Res 2010;302:499–505; 6Mahil SK. Br J Dermatol 2020;182:1158–66; 7Hongbo Y. J Invest Dermatol 2005;125:659–64.  
Author Contributions: Substantial contributions to study conception/design, or acquisition/analysis/interpretation of data: KG, PF, PR, KD, AP, CEMG, MW, VV, FS, VC, JFM; drafting of the publication, or revising it critically for important intellectual content: KG, PF, PR, KD, AP, CEMG, MW, VV, FS, VC, JFM; final approval of the publication: KG, PF, PR, KD, AP, CEMG, 
MW, VV, FS, VC, JFM. Author Disclosures: KG: Honoraria and/or research support from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Dermira, Eli Lilly, Janssen, Novartis, Pfizer, Sun Pharma, and UCB Pharma; PF: Grant support from AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Merck, Novartis, Pfizer, Sanofi, and Sun Pharma; 
Investigator for AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Botanix, Celgene, Celtaxsys, CSL, Cutanea, Dermira, Eli Lilly, Galderma, Genentech, Geneseq, GSK, Hexima, Janssen, LEO Pharma, Merck, Novartis, Pfizer, Regeneron, Reistone, Roche, Sanofi Genzyme, Sun Pharma, UCB Pharma, and Valeant/Bausch Health; served on the 
advisory board for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Galderma, Janssen, LEO Pharma, Mayne Pharma, Merck, Novartis, Pfizer, Sanofi Genzyme, Sun Pharma, UCB Pharma, and Valeant/Bausch Health; consultant for Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, UCB Pharma, and Wintermute; received travel grants from AbbVie,  
Eli Lilly, Janssen, LEO Pharma, Merck, Novartis, Pfizer, Roche, and Sanofi; speaker for or received honoraria from AbbVie, Celgene, Eli Lilly, Galderma, Janssen, LEO Pharma, Merck, Novartis, Pfizer, and Roche; PR: Research grants due to being principal investigator from AbbVie, Arcutis, Bristol Myers Squibb, Centocor, Dermavant, Eli Lilly, Kadmon, Merck, Novartis, 
Pfizer, Sun Pharma, and UCB Pharma; KD: Received grants/investigator for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Regeneron, Sienna, Stiefel, and UCB Pharma; Speaker’s Bureau for Novartis (non-promotional only); consultant/advisory board for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, 
Ortho Dermatologic, Pfizer, Sienna, Stiefel, and UCB Pharma; AP: Investigator and/or speaker and/or advisor for AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Celgene, Eli Lilly, Galderma, GSK, Hexal, Janssen, LEO Pharma, MC2, Medac, Merck Serono, Mitsubishi Pharma, MSD, Novartis, Pfizer, Regeneron, Roche, Sandoz, Schering-Plough, Tigercat 
Pharma, and UCB Pharma; CEMG: Honoraria and/or grants from AbbVie, Almirall, BMS, Celgene, Eli Lilly, Galderma, LEO Pharma, Janssen, Novartis, Pfizer, Sandoz, and UCB Pharma; MW, VV, FS, VC: Employees of UCB Pharma; JFM: Consultant and/or investigator for AbbVie, Arena, Avotres, Biogen, Bristol Myers Squibb, Dermavant, Eli Lilly, EMD-Serono, Janssen, 
LEO Pharma, Merck, Novartis, Regeneron, Sanofi, Sun Pharma, Pfizer, and UCB Pharma. Acknowledgements: This study was funded by UCB Pharma. We would like to thank the patients and their caregivers in addition to all the investigators and their teams who contributed to this study. The authors acknowledge Mylene Serna, PharmD, UCB Pharma, Smyrna, 
GA, USA and Susanne Wiegratz, MSc, UCB Pharma, Monheim am Rhein, Germany for publication coordination; Eva Cullen, PhD, UCB Pharma, Brussels, Belgium for critical review; Kristian Clausen, MPH, Costello Medical, Cambridge, UK for medical writing and editorial assistance; and the Costello Medical Design Team for design support. All costs associated with 
development of this poster were funded by UCB Pharma.

Previously presented at EADV 2020 Virtual Congress  |  October 29–31

aBimekizumab dosing was 320 mg regardless of weight, while ustekinumab dosing was based on weight: patients  
≤100 kg at baseline received one ustekinumab 45 mg injection and one placebo injection, patients >100 kg at 
baseline received two ustekinumab 45 mg injections; bBE BRIGHT: NCT03598790.

Table 1 Baseline characteristics

aBimekizumab dosing was 320 mg regardless of weight, while ustekinumab dosing was based on weight: patients ≤100 kg at baseline received one ustekinumab 45 mg injection 
and one placebo injection, patients >100 kg at baseline received two ustekinumab 45 mg injections; bIn each treatment group, one patient with mild IGA score was mistakenly 
enrolled.

Figure 2 Simultaneous achievement of PASI=0 and 
DLQI 0/1 at Weeks 16 and 52 (OC)a

N numbers represent the number of patients with both a PASI and DLQI assessment at that time point. aPatients 
randomized to placebo not shown.

aWeek 52 data not shown for patients randomized to placebo as they switched to bimekizumab treatment at Week 16. Denominators used represent the number of patients in 
that treatment group with an assessment at that time point for each type of measure (PASI or DLQI). Of all patients, 283 randomized to bimekizumab, 141 to ustekinumab and 69 
to placebo completed the study to Week 52.

Table 2 Number (%) of patients achieving absolute PASI scores and DLQI 0/1 (OC)

Bimekizumab 320 mg Q4W 
(n=321)a

Ustekinumab 45/90 mg Q12W 
(n=163)a

Placebo 
(n=83)

Age (years), mean ± SD 45.2 ± 14.0 46.0 ± 13.6 49.7 ± 13.6

Male, n (%) 229 (71.3) 117 (71.8) 60 (72.3)

Caucasian, n (%) 237 (73.8) 120 (73.6) 63 (75.9)

Weight (kg), mean ± SD 88.7 ± 23.1 87.2 ± 21.1 89.1 ± 26.4

Duration of psoriasis (years), mean ± SD 16.0 ± 11.6 17.8 ± 11.6 19.7 ± 13.8

PASI, mean ± SD 22.0 ± 8.6 21.3 ± 8.3 20.1 (6.8)

BSA (%), mean ± SD 29.0 ± 17.1 27.3 ± 16.7 27.0 ± 16.3

IGA, n (%)b

3: moderate 201 (62.6) 96 (58.9) 54 (65.1)

4: severe 119 (37.1) 66 (40.5) 28 (33.7)

DLQI total, mean ± SD 9.9 ± 6.3 11.0 ± 6.9 10.0 ± 6.8

Any prior systemic therapy, n (%) 267 (83.2) 132 (81.0) 64 (77.1)

Prior biologic therapy, n (%) 125 (38.9) 63 (38.7) 33 (39.8)

Absolute PASI
DLQI 0/1

PASI=0 PASI≤2

W
e

e
k

 4

Bimekizumab 48/318 (15.1) 148/318 (46.5) 120/320 (37.5)

Ustekinumab 2/161 (1.2) 10/161 (6.2) 18/161 (11.2)

Placebo 2/81 (2.5) 2/81 (2.5) 5/80 (6.3)

W
e

e
k

 1
6

Bimekizumab 188/307 (61.2) 273/307 (88.9) 216/308 (70.1)

Ustekinumab 35/156 (22.4) 84/156 (53.8) 69/156 (44.2)

Placebo 0/76 (0.0) 3/76 (3.9) 10/76 (13.2)

W
e

e
k

 5
2

a

Bimekizumab 207/277 (74.7) 263/277 (94.9) 240/277 (86.6)

Ustekinumab 63/139 (45.3) 98/139 (70.5) 103/141 (73.0)

80%

60%

40%

20%

100%

0%
Bimekizumab Ustekinumab

PASI≤2 
only

PASI≤2 +
DLQI 0/1 

70.5%

94.9%

59.7%

83.8%

n=321

n=163

n=83

Week 16Baseline Week 52

2–5 
weeks

Bimekizumab 320 mg Q4Wa

Bimekizumab 320 mg Q4WaPlacebo

Ustekinumab 45/90 mg Q12Wa

20 weeks 

after last 

dose: safety 

follow-up

Open-label

extension 

study

(BE BRIGHT)b 

Screening Initial treatment 
period

Active comparator period

Maintenance period 

4:1:2
randomization

N=567

Ustekinumab

Bimekizumab

Bimekizumab

Week 16 Week 52

Ustekinumab

PASI=0:

PASI=0 and DLQI 0/1:

Bimekizumab

Ustekinumab

61.2%

74.7%

45.3%

n=307 n=277

n=156 n=139

44.6% 68.6%

17.3% 40.3%

22.4%

Figure 3 Simultaneous achievement of PASI≤2 and 
DLQI 0/1 at Weeks 16 and 52 (OC)a

N numbers represent the number of patients with both a PASI and DLQI assessment at that time point. aPatients 
randomized to placebo not shown. 

Ustekinumab

Bimekizumab

PASI≤2:

PASI≤2 and DLQI 0/1:

Bimekizumab

Ustekinumab

Bimekizumab

Week 16 Week 52

Ustekinumab

n=307 n=277

n=156 n=139

88.9%

83.8%

94.9%

34.6% 59.7%

70.5%

53.8%

65.1%